Escherichia coli phage pEC-S163-2.2 and its application and preparation

Through E. coli phage pEC-S163-2.2 and its preparation, the problem of multidrug-resistant E. coli infection is solved, effective inhibition and killing of these bacteria is achieved, new treatment and disinfection methods are provided, and high safety and Wide applicability.

CN116103248BActive Publication Date: 2024-11-22YOUYIBANG BIOTECHNOLOGY (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310256422.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-16
Publication Date
2024-11-22
Estimated Expiration
2043-03-16

AI Technical Summary

Technical Problem

Multidrug-resistant E. coli infection has caused clinical treatment difficulties and has become a global public health problem. It is difficult for the existing technology to effectively inhibit and kill these bacteria.

Method used

Provides an E. coli phage pEC-S163-2.2 and its preparation, which has a wide host spectrum and a fast latency, can effectively inhibit and kill multidrug-resistant E. coli, and has high safety and extensive temperature and acid-base tolerance. .

Benefits of technology

Escherichia coli phage pEC-S163-2.2 has a strong disinfection effect on multidrug-resistant E. coli, with short incubation period and small toxic and side effects. It is suitable for the preparation of drugs to prevent and treat multidrug-resistant E. coli, significantly improving the treatment and protection effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116103248B_ABST
    Figure CN116103248B_ABST
Patent Text Reader

Abstract

This application provides an *Escherichia coli* bacteriophage pEC-S163-2.2, its application, and a formulation. This *Escherichia coli* bacteriophage pEC-S163-2.2 is deposited at the Guangdong Provincial Microbial Culture Collection Center (GDMCC), located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCCNo: 63107-B1. This application also provides a formulation comprising the aforementioned *Escherichia coli* bacteriophage pEC-S163-2.2. Furthermore, this application provides the use of *Escherichia coli* bacteriophage pEC-S163-2.2 in the preparation of formulations for the prevention and treatment of multidrug-resistant *Escherichia coli* infections. *Escherichia coli* bacteriophage pEC-S163-2.2 shows promising application prospects in the prevention and treatment of *Escherichia coli* infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and more specifically, to Escherichia coli phages and applications and preparations thereof. Background Art

[0002] Escherichia coli is an opportunistic Gram-negative bacillus belonging to the family Enterobacteriaceae and the genus Escherichia. In addition to gastrointestinal infections, it can also cause urinary tract infections, arthritis, meningitis, and septicemic infections. Among them, O157:H7 Escherichia coli is the most harmful, and it is a member of the EHEC (Enterohemorrhagic Escherichia coli) family. When it comes to O157:H7 Escherichia coli, it can be said that it has a bad record: the United States has experienced three outbreaks of O157:H7 Escherichia coli in 1982, 1984, and 1993; Japan had a pandemic in 1996 that affected more than 9,000 people. The main symptom of infection with O157:H7 Escherichia coli is bloody diarrhea, and severe cases may be accompanied by hemolytic uremic syndrome (HUS), which is life-threatening. Since E. coli O157:H7 is very harmful and can be widely spread among the population through food and drinking water, the food hygiene authorities have listed E. coli O157:H7 as a routine testing item. The newly discovered E. coli O104 is also a type of EHEC. The symptoms of infection are similar to those of E. coli O157:H7, and the virulence is more severe. E. coli is also the most common in life and is easy to acquire drug resistance. One of the most serious challenges in modern medicine is to fight hospital infections caused by multidrug-resistant bacteria in the ESKAPE (Enterococcus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter) group. These pathogens are extremely dangerous because new and more complex resistance mechanisms may emerge. E. coli disease is most common in clinical practice. According to the 2021 National Bacterial Resistance Monitoring Report, E. coli ranks first (18.98%) among clinically isolated bacteria. It can be seen that infection with E. coli is a problem that cannot be ignored. In recent years, the emergence of multidrug-resistant and extensively drug-resistant Escherichia coli has brought great difficulties to clinical treatment and has also become a global public health issue.

[0003] Bacteriophages are viruses that infect microorganisms such as bacteria, fungi, algae, actinomycetes, spirochetes, and cyanobacteria. They are widely distributed in nature. Wherever there are microorganisms, such as bacteria and fungi, there are corresponding bacteriophages. Bacteriophages were first discovered by microbiologists Frederick Twor and Felix d'Herelle in 1915 and 1917 respectively. They are the most abundant and diverse organisms on earth, with a wide variety of species and huge numbers, 10 to 100 times that of bacteria, with about 1×10 31species. Bacteriophages must use bacteria and other microorganisms as hosts to reproduce, and their size is usually between 20 and 200nm. As a natural killer of bacteria, it has been used to treat bacterial infections since its discovery. Phage therapy has been widely used in pathogen prevention and control in many fields such as medicine, animal husbandry and veterinary medicine, and food hygiene. Compared with antibiotics, phages are easy to obtain and isolate; they are not easy to develop drug resistance; they have strong host specificity and only eliminate target bacteria, and will not pose a threat to other normal flora in humans and animals; they are highly safe and are normal symbionts of humans and animals. In addition, they can reproduce rapidly and in large numbers in the presence of a host. Due to the increasingly serious problem of bacterial resistance, phages have great potential as an alternative option for treating infectious bacterial diseases. Summary of the invention

[0004] In view of the above technical problems, the present invention provides an Escherichia coli phage and its application in inhibiting and killing multi-drug resistant Escherichia coli, aiming to provide a new treatment plan for Escherichia coli infection and a potential new disinfection method for environmental and feed pollution caused by Escherichia coli.

[0005] The present application provides an Escherichia coli phage pEC-S163-2.2, wherein the Escherichia coli phage pEC-S163-2.2 is deposited in Guangdong Province Microbiological Culture Collection Center (GDMCC) with a deposit number of GDMCC No: 63107-B1.

[0006] The present application also provides a preparation comprising the Escherichia coli phage pEC-S163-2.2 as described above.

[0007] The present application also provides the use of Escherichia coli phage pEC-S163-2.2 in the preparation of a preparation for preventing and treating Escherichia coli infection.

[0008] Compared with the prior art, the present invention has the following beneficial effects:

[0009] (1) Escherichia coli phage pEC-S163-2.2 is a broad host spectrum phage. This phage not only has a good disinfecting effect on its multidrug-resistant host strain Escherichia coli MPEB0000337, but also has a strong disinfecting effect on the other five strains of Escherichia coli MPEB0000278, MPEB0009307, MPEB0001297, MPEB0012068 and MPEB0004456. It has a broad antibacterial spectrum and can be used to prepare drugs for the prevention and treatment of multidrug-resistant Escherichia coli. The above strains are all from Unibond Biotech (Shanghai) Co., Ltd.;

[0010] (2) The Escherichia coli phage pEC-S163-2.2 has a short incubation period (10 minutes) and can quickly kill the host bacteria in the culture medium. It has low toxicity and side effects, is highly safe, has a wide temperature and acid-base tolerance range, and has good hydrophilicity. It is easy to make into sprays and injections, has a good inhibitory and killing effect on the proliferation of Escherichia coli, and has a good therapeutic and protective effect on animals infected with multidrug-resistant Escherichia coli. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is a plaque picture of the Escherichia coli phage pEC-S163-2.2 of the present invention.

[0012] Figure 2 It is a transmission electron microscope image of the Escherichia coli phage pEC-S163-2.2 of the present invention.

[0013] Figure 3 It is a one-step growth curve diagram of the Escherichia coli phage pEC-S163-2.2 of the present invention.

[0014] Figure 4 It is a schematic diagram showing the effect of temperature on the activity of the Escherichia coli phage pEC-S163-2.2 of the present invention.

[0015] Figure 5 This is a schematic diagram showing the effect of pH on the activity of the Escherichia coli phage pEC-S163-2.2 of the present application.

[0016] Figure 6 It is a schematic diagram of sterilization in the culture medium of the Escherichia coli phage pEC-S163-2.2 of the present invention.

[0017] Figure 7 It is a schematic diagram of the treatment of G. mellonella larvae infected with E. coli by the E. coli phage pEC-S163-2.2 of the present invention.

[0018] The Escherichia coli phage (Escherichia coli phage) pEC-S163-2.2 provided by the present invention has a taxonomic name of Escherichia coli phage, was deposited in the Guangdong Provincial Microbiological Culture Collection Center (GDMCC) on January 1, 2023, and the deposit number is: GDMCC No: 63107-B1; the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. DETAILED DESCRIPTION

[0019] The following examples may enable those skilled in the art to more fully understand the present invention, but are not intended to limit the present invention in any way.

[0020] The strains, reagents and culture media involved in the embodiment are:

[0021] The host bacteria used in the experiment are multidrug-resistant Escherichia coli clinical strains from Unibond Biotech (Shanghai) Co., Ltd. with the catalog number: MPEB0000337.

[0022] MH broth (1 L): Weigh 21.0 g of MH broth, dissolve in 1000 mL of ddH2O, and sterilize under high pressure at 121°C for 20 min.

[0023] 0.7% MH (B) semisolid medium (1 L): weigh 21.0 g of MH broth and 7.0 g of agar powder, add ddH2O to 1000 mL, and sterilize under high pressure at 121°C for 20 min.

[0024] MH(A) medium (1 L): Weigh 36.5 g of MH(A) medium (Mueller-Hinton Agar), add 1000 mL of ddH2O, sterilize at 121°C for 20 min, cool to 50°C, pour onto a plate, cool and solidify, and then invert for later use.

[0025] SM buffer, PBS, DNaseⅠ, RNase A, PEG8000, NaOH, HCl, and NaCl were commercially available.

[0026] Example 1

[0027] Isolation of Escherichia coli phage pEC-S163-2.2

[0028] The host bacteria S163-2 was streaked and inoculated on MH(A) medium. After culturing overnight, a single clone was picked and inoculated into 5 mL of liquid culture medium. After shaking culture at 37°C for 12 h, it was used as the host bacteria culture for later use.

[0029] The sample was collected from sewage in Guangzhou. The sewage sample was centrifuged at 4°C and 8000rpm for 10min, and the supernatant was filtered with a 0.22μm filter membrane. Take 1000μL of the filtrate, add 100μL of the host bacterial solution, and then add 5mL of MH (B) culture medium, and culture it in a constant temperature oscillator for 12h. Centrifuge the above culture at 4°C and 8000rpm / min for 10min, and filter the supernatant with a 0.22μm filter membrane to sterilize, forming a stock solution containing phages, i.e., phage suspension.

[0030] Pipette 100 μL of the above-mentioned spare host bacteria culture into a 10 mL sterile centrifuge tube, pour in 8 mL of preheated semi-solid culture medium, invert and mix well, then pour on a solid plate. After drying, divide the plate into two areas, take 10 μL of the above-mentioned phage suspension and drop it on one side of the plate, and drop the same volume of PBS on the other side as a blank control. After drying naturally, invert and culture in a 37°C incubator for 12 hours, and observe whether there is plaque formation in the phage drop area. If plaques are formed, it proves that phages exist.

[0031] Take another 100 μL of the above phage suspension and dilute it 10 times. -5 ~10 -8 100μL of the diluent was mixed with the same volume of host bacterial solution, let it stand for 10 minutes, add 5-8mL of 0.7% semi-solid MH (B) medium at about 50℃, evenly spread on the pre-prepared solid MH (B) plate, and observe the growth of plaques after culturing at 37℃ for 12 hours. Pick a single transparent, uniform-sized plaque into an EP tube containing MH (B) and place it at 4℃ for 4 hours. Take 100μL of the above solution again and dilute it 10 times, take 100μL of the diluent and make a double-layer plate with the same volume of host bacterial solution. Repeat this 3-5 times to obtain phages with uniform plaque size, store at 4℃ for later use.

[0032] Plaque results Figure 1 As shown, the phage can form clear plaques in agar culture medium with clear and regular edges and a diameter of about 1.5 mm, which is a typical lytic phage.

[0033] Example 2

[0034] Amplification and Purification of Escherichia coli Phage pEC-S163-2.2

[0035] Take 0.1 mL of the phage preservation solution prepared in Example 1 and 0.1 mL of the host bacteria culture prepared in Example 1 in a test tube and act for 15 min, add 10 mL of MH (B) liquid culture medium, culture at 37° C. for 12 h, centrifuge at 4° C. and 8000 rpm for 20 min, take the supernatant, filter with a 0.22 μm filter membrane, and the filtrate is the phage lysate.

[0036] PEG purification: DNaseI and RNaseA were added to the phage lysate to a final concentration of 1 μg / mL, and the mixture was allowed to stand at room temperature for 30 min. NaCl was added to a final concentration of 1 mol / L and placed on ice for 2 h. The mixture was centrifuged at 4°C and 10,000 rpm / min for 20 min. The supernatant was added with PEG8000 at a final concentration of 10%, and placed on ice for 12 h. The mixture was then centrifuged at 4°C and 10,000 rpm / min for 20 min. The supernatant was discarded carefully, and the mixture was inverted for 5 min to allow the liquid to drain. 2 mL of SM buffer was added to resuspend the precipitate, and an equal volume of chloroform was added and gently shaken for 30 s. The mixture was centrifuged at 4°C and 5,000 rpm / min for 15 min to separate the organic phase and the hydrophilic phase. The hydrophilic phase containing the phage particles was recovered to obtain a purified phage suspension.

[0037] Example 3

[0038] Observation of Escherichia coli phage pEC-S163-2.2 by transmission electron microscopy

[0039] The purified phage suspension of Example 2 was observed under an electron microscope. The purified phage suspension of Example 2 was dropped on a copper sheet and allowed to precipitate naturally for 2 to 3 minutes. Excess liquid was removed with filter paper and stained with a drop of 2% phosphotungstic acid (PTA, 2% w / v). After drying at room temperature, the suspension was observed under a transmission electron microscope. The results are shown in FIG. Figure 2 As shown in Figure 2, the phage pEC-S163-2.2 is a long-tailed phage with a regular icosahedral structure and a head diameter of about 89.41 nm.

[0040] The phage was named pEC-S163-2.2 and deposited in Guangdong Microbial Culture Collection Center (GDMCC), with the deposit address: Institute of Microbiology, Guangdong Academy of Sciences, No. 100, Xianlie Middle Road, Guangzhou, Guangdong, with the deposit number GDMCC No: 63107-B1.

[0041] Example 4

[0042] Determination of one-step growth curve of Escherichia coli phage pEC-S163-2.2

[0043] Mix the reserved host bacteria culture in Example 1 with the reserved phage in Example 1 (the infection multiplicity is about 0.001), incubate at 37°C for 10 minutes, then centrifuge at 10,000 rpm / min for 1 minute, discard the supernatant, and wash the precipitate twice with MH (B) liquid culture medium. Resuspend the precipitate with 5 mL of preheated MH (B) liquid culture medium, and quickly place it in a 37°C shaker for shaking culture. Starting from 0 min, take 200 μl of the culture every 10 minutes, centrifuge at 4°C and 10,000 rpm / min for 2 minutes to remove the bacteria, take the supernatant and dilute it tenfold to the appropriate concentration, and determine the phage titer by the double-layer plate method. Draw a one-step growth curve with the sampling time as the horizontal axis and the logarithm of the phage titer as the vertical axis. The results of the one-step growth curve are shown in the figure. Figure 3 As shown, the incubation period of infection with the host bacteria is 10 minutes, and it enters the plateau phase at the 50th minute.

[0044] Example 5

[0045] Temperature and pH tolerance experiment of Escherichia coli phage pEC-S163-2.2

[0046] Take 6 sterile EP tubes, add 1 mL of the phage prepared in Example 1 to each tube, and incubate at -20°C, 4°C, 25°C, 37°C, 50°C, 60°C, and 70°C for 60 min, and then measure the phage titer. Figure 4 As shown: the phage can still maintain high activity at a temperature of -20℃ to 37℃ for 1 hour, and can withstand high temperatures of 50℃ and 60℃, but the phage completely loses its activity after incubation at 70℃ for 1 hour.

[0047] Take 7 portions of 100 μL of the phage prepared in Example 1 and put them into MH (B) (900 μL) with pH values ​​of 2, 4, 6, 7, 8, 10, and 12, respectively, and react at 37°C for 1 hour. Then, the titer of the phage after the reaction is determined by the double-layer method. The test results are as follows: Figure 5 As shown: the titer of E. coli phage pEC-S163-2.2 changes little in an environment with a pH value of 6 to 8, and the activity remains basically unchanged. After acting in an environment with a pH of 4 for 1 hour, the titer is significantly lower than that in an environment with a pH of 6, and it is completely inactivated after being in an environment with a strong acid of pH 2 and a strong base of pH 12 for 1 hour.

[0048] Example 6

[0049] Host spectrum analysis of Escherichia coli pEC-S163-2.2

[0050] The host spectrum of E. coli phage pEC-S163-2.2 was analyzed using 15 strains of E. coli. The above strains are all from Unibond Biotechnology (Shanghai) Co., Ltd., and the product numbers are shown in Table 1. The host spectrum of E. coli pEC-S163-2.2 was analyzed as follows: 100 μL of the culture solution of 15 strains of bacteria was placed in a 10 mL sterile centrifuge tube, and preheated semi-solid culture medium was added. After inversion and mixing, pour it on a solid plate. After solidification, 10 μL of phage solution was dripped on the surface of the plate, and PBS was used as a negative control. After drying, invert and culture at 37°C for 12 hours. If plaques are produced, it is recorded as "+", otherwise it is recorded as "-". The results are shown in Table 1. E. coli phage pEC-S163-2.2 can not only lyse the multi-drug resistant host bacteria S163-2, but also the E. coli M2158-1Ar from the hospital and the multi-drug resistant bacteria M172-1 isolated from the Malayan pangolin. Table 1 shows the host spectrum of E. coli phage pEC-S163-2.2.

[0051] Table 1

[0052]

[0053] Example 7

[0054] Bactericidal effect of Escherichia coli phage pEC-S163-2.2 in culture medium

[0055] Example 1 Alternative host bacteria S163-2 culture adjustment OD 600 to 0.15 (the number of viable bacteria is about 6×10 7 cfu) and set aside in an ice bath. Take 4 centrifuge tubes, mark the control group, MOI = 100, 1, 0.01, add 9 ml of the culture in the ice bath, add 9 ml of MH (B) to the control group, and add 9 ml of the corresponding phage solution to the experimental group. Quickly divide into 1.5 ml centrifuge tubes and place them in a 37 ° C constant temperature shaker for culture. Measure the absorbance of the culture at 600 nm every 3 hours. With time as the horizontal axis and OD as the horizontal axis, the absorbance of the culture at 600 nm is 90%. 600 The value is taken as the vertical axis, and the in vitro inhibition curve is drawn.

[0056] The results of the bacteriophage killing experiment are as follows Figure 6 As shown, the control group (S163-2 + MHB) had an OD of 600 The value showed an upward trend, and the bacterial count gradually increased, and entered a plateau phase after 15 hours. When the bacteriophage pEC-S163-2.2 was added at different infection multiplicities, the curve trend was roughly the same: in the first 6 hours, OD 600 The value was less than 0.07 and significantly lower than that of the control group, indicating that Escherichia coli S163-2 was lysed in large quantities; an increasing trend appeared after 6 hours, but the value was always lower than that of the control group.

[0057] Example 8

[0058] Protection experiment of Escherichia coli phage pEC-S163-2.2 based on the wax moth larvae model

[0059] The phage protection test was conducted using the larvae of the greater wax moth as a model to evaluate the anti-infection potential of the phage. 60 healthy larvae weighing about 250-300 mg were selected and randomly divided into 6 groups, with 10 in each group. They were starved the day before the experiment to reduce their immunity. During the experiment, the larvae were surface disinfected with a cotton swab containing 75% ethanol. Grouping was performed according to Table 2, and the corresponding liquid was injected using a microsyringe: 10 μL of the first injection was injected through the left foot of the first tail, and 0.5 h later, the second injection was injected on the opposite side. After the injection, the larvae were placed in a culture dish and cultured in a dark environment at 37 ° C (fasting), observed every 3 h, and the survival rate of the greater wax moth larvae was recorded for 48 consecutive hours. (When the greater wax moth larvae did not show any movement under tactile stimulation, they were considered dead.) Table 2 shows the grouping information of the greater wax moth.

[0060] Table 2

[0061]

[0062] Results According to the SPSS software Kaplan-Meier analysis, the survival rate of the wax moth larvae infected with the first group of E. coli S163-2 but not injected with phage was only 20% at 48h; while the survival rates of the wax moth larvae in the fourth, fifth and sixth groups injected with phage at MOI=100, 1 and 0.01 were 90%, 70% and 80% at 48h, which were significantly higher than those in the first group (p<0.05), indicating that the phage had a significant protective effect on the wax moth larvae. At the same time, the survival rate of the third group injected with saline and phage was still 100% only at 48h, and there was no difference in survival rate with the second group injected with PBS only, proving that phage injection is safe for wax moth larvae.

[0063] In summary, Escherichia coli phage pEC-S163-2.2 has good application prospects in the prevention, control and treatment of Escherichia coli infections.

[0064] It should be understood by those skilled in the art that the above embodiments are merely exemplary embodiments and that various changes, substitutions and alterations may be made without departing from the spirit and scope of the present invention.

Claims

1. An Escherichia coli phage ( Escherichiacoliphage )pEC-S163-2.2, deposited in Guangdong Microbial Culture Collection Center (GDMCC), deposit address: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, deposit number: GDMCC No: 63107-B1.

2. A preparation comprising the Escherichia coli phage pEC-S163-2.2 according to claim 1.

3. Use of the Escherichia coli phage pEC-S163-2.2 as claimed in claim 1 in the preparation of a preparation for preventing and treating multidrug-resistant Escherichia coli infection.